Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) (TX) vs Veeva Systems (VEEV) Price & Performance

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)Trade
Veeva SystemsTrade

Price performance (Past 24H)

Key statistics

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) vs Veeva Systems — how do they compare? Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) trades at $58.55 (market cap $11.58B), while Veeva Systems trades at $296 (market cap $48.84B). The key difference: Veeva Systems is far larger — about 4.2× Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)'s market cap, and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) pays a 3.73% dividend while Veeva Systems pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) for 0 Days and Veeva Systems for 6 Days on average.

TXVEEV
Market Cap
$11.58B$48.84B
Volume
456,3672,253,175
Sector
Basic MaterialsTechnology
52-Week High
$58.99$301.63
52-Week Low
$35.26$151.43
Typical Hold Time
0 Days6 Days
Enterprise Value
$11.90B$41.75B
Dividend Yield
3.73%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)

Ternium (TX) trades at $58.99, up 1.81% with strong Q2 2026 earnings beating estimates by 43%. The stock shows solid fundamentals with attractive valuation metrics including P/E of 16.39 and P/S of 0.72. Recent analyst upgrades to Strong Buy highlight improving sentiment as Mexico's steel recovery drives operational momentum and the $4B Pesqueria project promises future capacity growth.

The stock offers value with 7% dividend yield projections and 14.5% upside to $65.52 fair value. Key risks include steel price volatility and trade uncertainty, but declining CapEx should boost free cash flow above 15% yield. Analyst consensus at $57.17 with 50% Buy ratings supports cautious optimism for continued recovery.

Veeva Systems

Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.

Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TX
100% Buy0% Sell
Avg holding period · 0 Days
VEEV

No sentiment data available yet.

Top news

Latest headlines on both assets

About Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)

Ternium S.A. is a Luxembourg-headquartered steel producer operating an integrated production system, from mining through finished flat and long steel products. It runs 18 production plants and two mining operations across Argentina, Brazil, Colombia, Guatemala, Mexico, and US, serving the automotive, construction, appliance, and energy industries.

Read more on TX →

About Veeva Systems

Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.

Read more on VEEV →